Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Key takeaways of Q3FY22 quarter & conference call highlights
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
India business grew 11.8% YoY vs mid-single digit industry growth.
Subscribe To Our Newsletter & Stay Updated
